|Podcasts|March 3, 2011
Merck's Biosimilars Business, from Parexel's Perspective
Advertisement
Merck's Biosimilars Business, From Parexel's Perspective
Josef von Rickenbach, Chairman and CEO of Parexel, discusses why Parexel won the Merck biosimilars’ business, differences in recruitment for biosimilars, and trends for 2011, including the 20-year promise of technology now being realized.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
2
How the FDA’s CNPV Program Is Reshaping Trial Operations and Accelerated Review Strategies
3
Voyxact Lands FDA Accelerated Approval Following Positive Results in Phase III VISIONARY Trial
4
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
